EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Outcomes and risk factors of hemorrhage in patients with resected brain metastases

Melisa S Guelen iD, Kiarash Ferdowssian, Niklas Jung, Hava N Celik, Andrea Dell'Orco, Semil Eminovic, Anton Früh, Majd Samman, Güliz Acker, Arend Koch, Helena Radbruch, Michael Scheel und 6 weitere

International Journal of Cancer · 2026

DOI: 10.1002/ijc.70250 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Melisa S Guelen und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Be…. Hauptthemen laut MEDLINE: Brain Neoplasms, Intracranial Hemorrhages. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Brain metastases (BrMs) may present with intralesional or intracranial hemorrhage (ICH), yet risk factors and outcomes remain unclear. This monocentric cohort study at Germany's largest neurosurgical clinic included 973 adults undergoing BrM resection (2010–2024), with histopathologically confirmed etiologies and known tumor burden. Based on pre‐operative CT or MRI, 880 patients were categorized as non‐hemorrhagic (non‐hBrM), presenting with intralesional hemorrhage (hBrM), or with ICH of ≥30 mm diameter (ICH‐BrM). Risk factors for hBrM and ICH‐BrM were assessed, and overall survival (OS) and progression‐free survival (PFS) were analyzed using Kaplan‐Meyer methods. Of 880 patients, 560 (63.6%) were non‐hBrM, 243 (27.6%) hBrM, and 77 (8.8%) ICH‐BrM. ICH‐BrM had larger tumor volume (21 cm 3 , IQR 13–34) than hBrM (14 cm 3 , IQR 6–28) and non‐hBrM (12 cm 3 , IQR 6–21) ( p adjust = .017), correlated with lower post‐op Karnofsky index ( p adjust = .047), dsGPA score ( p adjust = .032), and more BrMs ( p adjust = .004). Pre‐operative antithrombotic use did not differ between groups ( p adjust = .32). Melanoma was more common in hBrM (27.8%) and ICH‐BrM (38.0%), predicting ICH (OR 2.95, p < .001) along with NSCLC (OR 1.64, p < .001). ICH did not independently predict worse OS (HR 1.23, p = .38). Worse OS was linked to larger tumor volume (HR 1.35, p = .002), extracranial metastases (HR 1.77, p < .001), and older age (HR 1.53, p < .001), while KPS >80% (HR 0.77, p < .01), solitary BrM (HR 0.62, p = .002), and adjuvant treatments ( p < .001) predicted improved OS. ICH is associated with larger tumors and melanoma but is not an independent OS predictor. Tumor burden, extracranial metastases, and adjuvant treatments drive BrM survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsIntracranial HemorrhagesHumansMaleFemaleRisk FactorsMiddle AgedAgedAdultRetrospective StudiesTumor BurdenPrognosisMagnetic Resonance ImagingGermanyTomography, X-Ray ComputedAged, 80 and over

Stichwörter der Autor:innen

anticoagulantshemorrhagic brain metastasisintracranial hemorrhagemelanomasurvival

Autor:innen und Institutionen

  • Department of Neurosurgery, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Institute of Neuroradiology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA.
  • Department of Radiology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • BIH Biomedical Innovation Academy, BIH Charité Junior Digital Clinician Scientist Program, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Department of Neuropathology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

ORCID-Profile: Melisa S Guelen

Zitieren

APA

Guelen, M. S., Ferdowssian, K., Jung, N., Celik, H. N., Dell'Orco, A., Eminovic, S., Früh, A., Samman, M., Acker, G., Koch, A., Radbruch, H., Scheel, M., Wattjes, M. P., Onken, J., Vajkoczy, P., Hecht, N., Nawabi, J., & Wasilewski, D. (2026). Outcomes and risk factors of hemorrhage in patients with resected brain metastases. International Journal of Cancer. https://doi.org/10.1002/ijc.70250

Vancouver

Guelen MS, Ferdowssian K, Jung N, Celik HN, Dell'Orco A, Eminovic S, et al. Outcomes and risk factors of hemorrhage in patients with resected brain metastases. International Journal of Cancer. 2026. doi:10.1002/ijc.70250

BibTeX
@article{Guelen2026,
  author = {Guelen, Melisa S and Ferdowssian, Kiarash and Jung, Niklas and Celik, Hava N and Dell'Orco, Andrea and Eminovic, Semil and Früh, Anton and Samman, Majd and Acker, Güliz and Koch, Arend and Radbruch, Helena and Scheel, Michael and Wattjes, Mike P and Onken, Julia and Vajkoczy, Peter and Hecht, Nils and Nawabi, Jawed and Wasilewski, David},
  title = {Outcomes and risk factors of hemorrhage in patients with resected brain metastases},
  journal = {International Journal of Cancer},
  year = {2026},
  doi = {10.1002/ijc.70250}
}
Kostenlos starten →